Evidence map›Paper›PMID 20026359›Full record

ReviewMolecular and biochemical parasitology2010

Phospholipid and sphingolipid metabolism in Leishmania.

Kai Zhang, Stephen M Beverley

Abstract readReview
In one paragraph

Review in Molecular and biochemical parasitology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed.

  1. LABCG1 AffectsACS infectious diseases · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Molecular Mechanisms of Drug Resistance inPathogens (Basel, Switzerland) · 2024
    Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Fatty Acid Profiles ofPathogens (Basel, Switzerland) · 2022
    Article
  14. The lipidome ofFrontiers in cellular and infection microbiology · 2022
    Article
  15. Article
  16. Article
  17. Review
  18. Lipid and fatty acid metabolism in trypanosomatids.Microbial cell (Graz, Austria) · 2021
    Review
  19. Review
  20. TheFrontiers in cellular and infection microbiology · 2021
    Article

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Kai ZhangDepartment of Biological Sciences, Texas Tech University, Lubbock, TX 79409, USA. kai.zhang@ttu.edu
Stephen M Beverley

Funding

GLYCOSYLATION MUTANTS OF LEISHMANIAR01AI031078 · NIAID · WASHINGTON UNIVERSITY · PI BEVERLEY, STEPHEN M · 1992 to 2019
$11.4M
MOLECULAR GENETICS OF LEISHMANIA USING DNA TRANSFECTIONR01AI029646 · NIAID · WASHINGTON UNIVERSITY · PI BEVERLEY, STEPHEN M · 1990 to 2015
$9.3M
MECHANISM OF GENE AMPLIFICATION IN LEISHMANIAR01AI021903 · NIAID · WASHINGTON UNIVERSITY · PI BEVERLEY, STEPHEN M · 1985 to 2010
$2.6M
NIAID NIH HHS AI31078NIAID NIH HHS R01 AI021903NIAID NIH HHS R01 AI029646NIAID NIH HHS R01 AI031078
6 · The paper itself

Abstract

In many eukaryotes, phospholipids (PLs) and sphingolipids (SLs) are abundant membrane components and reservoirs for important signaling molecules. In Leishmania, the composition, metabolism, and function of PLs and SLs differ significantly from those in mammalian cells. Although only a handful of enzymes have been experimentally characterized, available data suggest many steps of PL/SL metabolism are critical for Leishmania viability and/or virulence, and could be a source for new drug targets. Further studies of genes involved in the synthesis (de novo and salvage) and degradation of PLs and SLs will reveal their diverse effects on Leishmania pathogenesis.

Indexed as

AnimalsBiosynthetic PathwaysLeishmaniaPhospholipidsSphingolipidsPhospholipidsSphingolipids

Identifiers

PMID20026359
PMCPMC2815228

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.